Psychedelic-Assisted Treatment for Alcohol Use Disorder
For adults with moderate-to-severe AUD who have failed standard therapies and lack contraindications, psilocybin-assisted psychotherapy is an emerging treatment option with the strongest evidence base among psychedelics, showing significant reductions in heavy drinking days compared to placebo, though it remains investigational and should only be administered within structured research protocols or specialized clinical programs with rigorous safety monitoring. 1
Evidence Quality and Current Status
The most robust data comes from a 2022 double-blind RCT published in JAMA Psychiatry 1, which demonstrated that psilocybin (25-40 mg/70 kg) combined with motivational enhancement therapy and CBT reduced heavy drinking days to 9.7% versus 23.6% with active placebo over 32 weeks—a clinically meaningful 13.9% absolute difference. This represents the highest-quality evidence for any psychedelic in AUD treatment 2.
However, standard evidence-based treatments remain first-line. Current guidelines emphasize that pharmacotherapy (naltrexone, acamprosate, or disulfiram) combined with CBT or another evidence-based behavioral therapy constitutes best practice for AUD 3. These FDA-approved medications are severely underutilized (only 2% clinical application) 4, and optimizing access to existing treatments should be the priority before considering experimental approaches.
When to Consider Psychedelic-Assisted Treatment
Psychedelic-assisted therapy may be appropriate for:
- Treatment-resistant AUD: Patients who have failed multiple trials of FDA-approved medications combined with behavioral therapy
- Moderate-to-severe AUD: DSM-5 diagnosis with ≥4 heavy drinking days in the past 30 days (based on trial inclusion criteria) 1
- Motivated patients: Those willing to engage in intensive psychotherapy (typically 12 weeks of structured sessions)
Absolute Contraindications
Based on safety data and clinical protocols 5, 1:
- Psychiatric: Personal or family history of psychotic disorders, bipolar disorder, active suicidal ideation
- Cardiovascular: Uncontrolled hypertension, cardiac arrhythmias, significant QTc prolongation
- Medical: Severe liver disease (though not explicitly studied, hepatic impairment affects drug metabolism)
- Substance use: Current use of other hallucinogens, major psychiatric medications that interact with serotonergic systems
- Age: Most trials exclude patients <25 or >65 years
Recommended Protocol (Based on Published Trials)
Pre-Treatment Phase (Weeks 1-4)
- Comprehensive psychiatric evaluation per APA guidelines 6, specifically assessing for psychotic symptoms, aggressive ideation, suicidal history, and substance use patterns
- Cardiovascular screening: Baseline ECG, blood pressure monitoring, cardiac history
- Laboratory assessment: Liver function tests, complete metabolic panel
- Psychotherapy initiation: Begin motivational enhancement therapy and CBT sessions (typically 4-8 preparatory sessions before first dose) 1
Medication Sessions (Weeks 4 and 8)
Psilocybin dosing 1:
- First session: 25 mg/70 kg (approximately 0.36 mg/kg)
- Second session: 25-40 mg/70 kg based on response and tolerability
- Administered in a controlled clinical setting with continuous monitoring
Safety monitoring during sessions:
- Continuous vital signs and ECG monitoring
- Two trained facilitators present throughout (typically 6-8 hours)
- Comfortable, non-clinical environment with music and eyeshades
- Immediate access to emergency medical support
Post-Treatment Phase (Weeks 9-32)
- Continued psychotherapy sessions (integration therapy)
- Regular follow-up for drinking outcomes using timeline followback methodology
- Monitoring for delayed adverse effects or psychiatric symptoms
Safety Considerations
Psilocybin has demonstrated a favorable safety profile in controlled settings 1:
- No serious adverse events reported in the pivotal trial
- Transient psychological distress ("bad trips") can occur but are managed with supportive care
- No evidence of addiction potential or withdrawal
Ibogaine carries significant cardiovascular risks 7:
- QTc prolongation and shortening observed in 5/9 patients in a recent pilot study
- Blood pressure alterations requiring medication in some cases
- Two patients needed intervention for psychomotor agitation, insomnia, and hypertension
- Requires more intensive cardiac monitoring than psilocybin
- Evidence base for AUD is much weaker than psilocybin
Ayahuasca and other psychedelics have insufficient evidence for AUD specifically 2.
Mechanisms and Therapeutic Framework
Emerging evidence suggests PAT works through multiple pathways 8:
- Neurobiological: Enhanced neuroplasticity, serotonergic modulation
- Psychological: Mystical experiences correlating with reduced drinking
- Therapeutic: Addressing underlying trauma, depression, and existential distress
- Contextual: Structured psychotherapy providing meaning-making and integration
Critical point: PAT should be conceptualized as a complex intervention, not merely pharmacotherapy 8. The psychotherapeutic framework is integral to outcomes—psilocybin alone without structured therapy has not been studied and is not recommended.
Practical Implementation
Current access pathways:
- Clinical trials: Phase 3 trials are underway; enrollment may be available at academic centers 5
- Specialized treatment programs: Limited availability in jurisdictions with regulatory approval
- Off-label use is not recommended: Lack of standardized protocols and safety monitoring outside research settings
Patient counseling points 9:
- Emphasize this is investigational treatment with promising but preliminary data
- Discuss potential for intense psychological experiences
- Address concerns about "bad trips" and relapse risk
- Highlight importance of commitment to full psychotherapy protocol
- Explain that spirituality and openness to introspection may enhance outcomes
Critical Caveats
The evidence remains limited 4:
- Only one high-quality RCT for psilocybin in AUD
- High expectancy bias in open-label studies
- Limited long-term follow-up data beyond 32 weeks
- Unclear generalizability to real-world settings outside research protocols
Optimize standard treatments first: Before pursuing psychedelic-assisted therapy, ensure patients have received adequate trials of:
- Naltrexone (oral or long-acting injectable)
- Acamprosate
- Disulfiram
- Combined with at least 12 weeks of evidence-based psychotherapy (CBT, motivational enhancement, contingency management)
Do not abandon proven therapies: Psychedelic-assisted treatment should complement, not replace, ongoing addiction medicine care including mutual support groups, case management, and treatment of co-occurring psychiatric disorders.